MonTa Biosciences successfully dose first patient in phase I clinical trial

MonTa Biosciences this week successfully enrolled and dosed the first cancer patient in our phase I clinical trial. Our drug MBS8 is a novel type of cancer immunotherapy with a Mode of Action not previously seen in cancer therapy was infused over one hour, and the patient managed the treatment very well. The study is running at phase I oncology units at Rigshospitalet and Herlev hospital in Copenhagen and two more sites in EU will open during the year. This is a great milestone for MonTa Biosciences, and we look forward to escalating dose levels in the coming dose cohorts during 2021.  Press Release April 2021 MonTa initiates phase I Final
Read more about the trial here: